Linked Life Data

18052771

Source:http://linkedlifedata.com/resource/pubmed/id/18052771

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2007-12-6
pubmed:abstractText
Central pontine myelinolysis represents a relatively contemporary neurologic entity in which an imbalance of water relative to alterations in the body's electrolyte levels induces characteristic demyelination in the central part of the basis pontis as well as extrapontine sites. The clinical scenario is typically one of chronic hyponatremia followed by a rapid correction to normonatremic or hypernatremic levels. This seemingly innocuous series of events can result in fatal consequences. Better understanding of the pathophysiology of this disorder provides avenues for clinical management, including use of steroids and organic osmoles, such as myoinositol. More recently, the introduction of a newer class of pharmacologic agents - the vasopressin receptor antagonists, known as vaptans, which induce an excretion of increased amounts of water without altered sodium or potassium excretion - is of particular interest. This review addresses classic approaches to the management of this disorder along with a discussion of newer pharmacologic agents that may become important therapeutic interventions in the clinical management of the osmotic myelinolysis syndrome.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1744-8360
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1791-7
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Current perspectives in the management of hyponatremia: prevention of CPM.
pubmed:affiliation
Department of Medicine, Rochester General Hospital, University of Rochester School of Medicine, Rochester, NY, USA. richard.stern@viahealth.org
pubmed:publicationType
Journal Article, Review